Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04905160 · ClinicalTrials.gov registry record · NA

Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions

A NA study of Heart Failure and ADHF, sponsored by Aventyn.

Recruiting
Registry status
NA
Development phase
1,000
Enrollment target
1
Study location

NCT04905160 is a NA study of Heart Failure and ADHF that is actively recruiting participants, run by Aventyn. The registered enrollment target is 1,000 participants, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04905160, a NA study of Heart Failure and ADHF, is actively recruiting participants, sponsored by Aventyn.

RECRUITING
Registry status
NA
Development phase
1,000 participants
Enrollment target
1
Study location

Study Summary

Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and/or right ventricular filling pressures and decreased cardiac output.

Interventions

  • OTHER COMPASSION Digital Biomarker

Study Locations (1)

Arizona

  • Multiple Locations - Phoenix

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2021-02-18
Est. Completion 2026-12-22
Phase NA

Sponsor

Aventyn

6 total trials

What the Registry Record Tells You About NCT04905160

The ClinicalTrials.gov registry entry for NCT04905160 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (51% lower). The listed sponsor is Aventyn, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which COMPASSION Digital Biomarker is the first listed.

NCT04905160 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT04905160 about?

NCT04905160 is a clinical study titled "Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions". Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinicall...

What is the current status of trial NCT04905160?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2021-02-18. Estimated completion is 2026-12-22.

What conditions does trial NCT04905160 study?

This clinical trial studies the following conditions: Heart Failure, ADHF, Acute MI.

What interventions are being tested in trial NCT04905160?

The interventions under investigation include: COMPASSION Digital Biomarker (OTHER).

Who is sponsoring clinical trial NCT04905160?

This trial is sponsored by Aventyn, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04905160 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.